We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
India’s Wockhardt is working to develop antimicrobial drugs to fight the emerging threat of superbugs, and the company has built a $40 million manufacturing facility in Dubai to produce them.